This study is looking at the safety and effectiveness of a special substance called P. vivax challenge agent (derived from PvHMB-CCE001) in healthy adults who have never had malaria. This agent is used to intentionally cause malaria in a controlled way. Researchers want to understand how malaria develops, how the body's immune system reacts, and how it spreads to mosquitoes. You might be able to join if you are a healthy adult between 18 and 54 years old, live near Washington D.C., and have a specific blood factor called Duffy antigen. The main goal is to see if this method of causing malaria is safe. The current status of this study is unclear, and it plans to enroll up to 300 participants.

Study design

This is a single-center, open-label study, meaning both you and the researchers will know what intervention you are receiving. It will involve up to 300 participants.

What's involved

You will be infected with the malaria parasite through an IV. You will likely develop symptoms within a week and will receive antimalarial treatment. You cannot live alone during parts of the study.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the time you receive the challenge agent until at least 21 days after you leave the hospital.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.